Fig. 4

CircNUP50 mediates platinum resistance in OC by regulating p53 ubiquitination by binding to UBE2T. A Silver staining of the RNA pull-down showed that circNUP50 bound to UBE2T and p53. B Protein–Protein Interaction (PPI) network analysis based on mass spectrometry data of circNUP50-binding proteins. C UBE2T expression with respect to OS of OC patients treated with cisplatin-containing regimens. D and E Molecular simulation results supported that circNUP50 could accurately dock with UBE2T or p53. F and G RNA binding protein immunoprecipitation (RIP) analysis and circRNA pull-down showed that p53 and UBE2T could interact with circNUP50. H Enhanced p53 expression levels after circNUP50 knockdown. I Co-immunoprecipitation experiments showed that p53 and UBE2T could bind to each other. J Co-localisation experiments showed that p53 and UBE2T were co-localised in the cytoplasm of SKOV3/DDP and A2780/DDP cells. K Cycloheximide (CHX) chase assays showed that the half-life of p53 in SKOV3/DDP cells was reduced when UBE2T was overexpressed. L The ubiquitination experiment showed that UBE2T overexpression and circNUP50 in SKOV3/DDP enhanced p53 ubiquitination